Highlights von AIDS2024
Hauptziel von WeltAidsKonferenzen ist es, ein Netzwerk zu schaffen von Wissenschaftlern, Aktivisten und Politikern. Die Vision ist eine Welt, in der HIV keine Gefahr mehr darstellt weder für die öffentliche Gesundheit noch für das individuelle Wohlergehen.
Das Programm der 25. Internationalen AIDS Konferenz umfasst in mehr als 200 Sessions alle Aspekte der HIV Pandemie und ist in sieben Tracks eingeteilt.
- Track A - Basic and translational science
- Track B – Clinical science
- Track C – Epidemiology and prevention science
- Track D - Social and behavioural sciences
- Track E – Implementation science, economics, systems and synergies
- Track F – Political science, laws, ethics, policies and human rights
- Cross Track
Clinical Science/Cross Track
-
An update from the ARTISTRY-1 study, which is evaluating bictegravir plus lenacapavir in virologically suppressed people with HIV who are otherwise unable to take a single-tablet regimen (25 July OAB2602)
-
An analysis of emerging dolutegravir resistance in children and adolescents living with HIV in Malawi (Poster WEPEB133)
-
Extended week 96 analysis data from the D2EFT trial on the extended efficacy and safety of dolutegravir-and darunavir- containing regimens (26 July OAB3804)
-
A study showing that PD-1 blockade combined with therapeutic vaccination leads to sustained suppression of SIV following ART discontinuation in macaques (24 July OAA1302)
-
A novel approach to treat HIV reservoirs in gut-associated lymphoid tissues using nanoformulations of combination antiretroviral therapy drugs (25 July OAA2805)
-
Results from diverse studies on DoxyPEP awareness, attitudes and use in multiple countries (Poster THEPEC212)
-
New insights on long-acting PrEP, including data from multiple countries on preferences around long-acting versus daily oral PrEP
-
The latest research on PrEP use and unmet need in PEPFAR-supported countries (26 July OAE0906LB and OAE0406LB)
-
Results from a real-world study evaluating the renal safety of tenofovir alafenamide (F/TAF) versus tenofovir disoproxil fumarate (F/TDF) for oral PrEP
-
The "next Berlin Patient", a person experiencing sustained HIV remission without antiretroviral therapy after heterozygous CCR5 WT/delta32 allogeneic hematopoietic stem cell transplantation
-
Important new data from the PURPOSE 1 trial, which found that twice-yearly injectable lenacapavir demonstrated 100% efficacy for HIV prevention in cisgender women
* Data from the PASO-DOBLE trial showing non-inferior efficacy and less weight gain when switching to DTG/3TC vs. BIC/FTC/TAF in virologically suppressed people living with HIV (OAB3606LB 26. July)
* Results of a pilot randomized controlled trial of doxycycline pre-exposure prophylaxis (DoxyPrEP) for prevention of bacterial STIs in gay men and other men who have sex with men who are living with HIV
* New findings from DTG Resist, a large multi-country study on dolutegravir resistance patterns in central, eastern, southern and western Africa
* Insights from a first-of-its-kind survey showing significant HIV stigma and discrimination among European healthcare workers
Political Highlights
-
An assessment of how Uganda’s Anti-Homosexuality Act 2023 has affected access to HIV and other healthcare services
-
New insights on how Russia's war on Ukraine has impacted access to HIV services
-
An important progress update on the global movement to end HIV criminalization
-
A global analysis showing the association between PrEP uptake and the robustness of national PrEP policies
-
A UNAIDS analysis of the current landscape and trends in domestic public spending on HIV in low- and middle-income countries
-
New estimates of the potential long-term human and economic cost of missing global HIV targets
Kollegen Fragen
Diese Seite weiter empfehlen
